Patient screening and stratification
ONCOLOGY, RECURRENT DISEASE, ADENOCARCINOMA, METASTATIC DISEASE
The patient inclusion criteria were as follows: age ≤ 18 years; histologically-proven gastric or esophagogastric junction adenocarcinoma; measurable and/or assessable metastatic disease according to RECIST 1.0 criteria, or locally recurrent disease associated with one or more measurable lymph nodes; Eastern Cooperative Oncology Group (ECOG) performance status > 2; progression after 1